As of November 14, 2026, Applied Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 3, 2026 (Form 8-K, February 3, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Applied Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Applied Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-03. Every row below is cited to the filing it comes from, and this page adds each new change as Applied Therapeutics, Inc. files it.
Also on the record for Applied Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | — | 5%+ stakes | Source |
| December 31, 2025 | Stake report, Schedule 13G/A, by Propel Bio Management, LLC | 4.2% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13G/A, by Alexandria Real Estate Equities, Inc. | 4.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 14.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 13.2% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 3.34% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 3.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Applied Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Applied Therapeutics, Inc. and the records around it.
Applied Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
Companies that share a holder
- Propel Bio Management, LLC also filed stake reports on 1 other company: Milestone Pharmaceuticals Inc. (Dec 2025)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Applied Therapeutics, Inc.
Get an email when Applied Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Applied Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Applied Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Applied Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-03 | Reported | not named in the filing | 8-K, 2026-02-03 |
New leaders reset buying decisions — get the Full Report on Applied Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Applied Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Applied Therapeutics, Inc.Every change, in the filing's words
Reported
Pursuant to the Merger Agreement, and effective at the Effective Time, each of Les Funtleyder, Teena Lerner, Jay S. Skylar and Stacy J. Kanter resigned as directors of the Company and members of any committee of the Company's board of directors.
- In connection with the Merger and as contemplated by the Merger Agreement, upon the consummation of the Merger, the sole director of Purchaser, James Harrison, became the sole director of the Company at the Effective Time.
- As a result of the Merger, as of the Effective Time, each of Les Funtleyder, Evan Bailey, Dale Hooks, Constantine Chinoporos, and Todd Baumgartner ceased serving as an officer of the Company.
- Further, pursuant to the Merger Agreement, effective as of the Effective Time, James Harrison, as President of Purchaser immediately prior to the Effective Time, became the President of the Company, and Andrea Reiner, as Secretary of Purchaser immediately prior to the Effective Time, became the Secretary of the Company.
Tools for this story
Each opens in a new tab, filled in for Applied Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
